What are the clinical indications, dosing regimens, contraindications, and common adverse effects of atovaquone?

Atovaquone: Clinical Overview

Atovaquone is a quinone antimicrobial agent primarily indicated for Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment in patients intolerant to trimethoprim-sulfamethoxazole, and as first-line therapy (combined with azithromycin) for babesiosis. 1

Clinical Indications

Primary Indications

PCP Prophylaxis:

• Adults and adolescents ≥13 years who cannot tolerate TMP-SMX 1
• HIV-infected children aged 1-3 months and >24 months: 30 mg/kg/day orally; children aged 4-24 months: 45 mg/kg/day orally 2
• Immunocompromised patients including transplant recipients, hematologic malignancies, and connective tissue disease patients on glucocorticoids 3, 4

PCP Treatment:

• Mild-to-moderate PCP (alveolar-arterial oxygen gradient ≤45 mm Hg) in adults and adolescents ≥13 years intolerant to TMP-SMX 1
• Pediatric dosing: 30-40 mg/kg/day in 2 divided doses; infants 3-24 months may require 45 mg/kg/day 5

Babesiosis (First-Line):

• Atovaquone plus azithromycin is the preferred initial therapy for babesiosis due to superior tolerability compared to clindamycin-quinine 6
• Adults: atovaquone 750 mg every 12 hours + azithromycin 500-1000 mg day 1, then 250 mg daily for 7-10 days 6
• Children: atovaquone 20 mg/kg every 12 hours (max 750 mg/dose) + azithromycin 10 mg/kg day 1 (max 500 mg), then 5 mg/kg daily 6
• Immunocompromised patients may require higher azithromycin doses (600-1000 mg/day) 6

Malaria Prophylaxis:

• Atovaquone-proguanil (Malarone) provides 95-100% efficacy for P. falciparum prophylaxis, including drug-resistant strains 7
• Dosing: 11-20 kg = 1 pediatric tablet (62.5 mg/25 mg) daily 2

Malaria Treatment:

• Uncomplicated P. falciparum: atovaquone-proguanil 250 mg/100 mg; <40 kg: 3 tablets daily for 3 days; >40 kg: 4 tablets daily for 3 days 8
• Second-line alternative when artemisinin-based combinations are contraindicated 8

Important Limitations

• NOT indicated for severe PCP (alveolar-arterial gradient >45 mm Hg) - efficacy not established 1
• NOT effective for patients failing TMP-SMX therapy - efficacy not studied 1
• Treatment of severe babesiosis requires clindamycin-quinine, not atovaquone-azithromycin 6

Dosing Regimens

Standard Dosing

PCP Prophylaxis:

• 1,500 mg (10 mL) once daily with food 1
• Low-dose alternative (750 mg/day) shows efficacy in lower-risk populations 4, 9

PCP Treatment:

• 750 mg (5 mL) twice daily with food for 21 days 1

Critical Administration Requirements:

• MUST be taken with food, preferably fatty meals - food increases bioavailability 1.4-fold 5
• Failure to administer with food results in suboptimal plasma concentrations and treatment failure 1

Special Populations

Gastrointestinal Disorders:

• Patients with malabsorption or diarrhea may have limited absorption resulting in suboptimal concentrations 1
• Consider alternative agents or monitor closely

Renal Impairment:

• No dosage adjustment required - atovaquone undergoes fecal excretion without renal elimination 1
• Increasingly used as cotrimoxazole alternative in renal impairment 3

Hepatic Impairment:

• Use with caution - hepatotoxicity reported 1

Contraindications

Absolute Contraindication:

• Known serious hypersensitivity reactions including angioedema, bronchospasm, throat tightness, or urticaria to atovaquone or any component 1

Adverse Effects

Common Adverse Effects (≥10%)

PCP Prophylaxis:

• Diarrhea (42%), rash (39%), headache (28%), nausea (26%), fever (25%) 1
• Treatment discontinuation required in 20-25% of patients 1

PCP Treatment:

• Rash including maculopapular (23%), nausea (21%), diarrhea (19%), headache (16%), vomiting (14%), fever (14%) 1
• Only 9% discontinued therapy (vs. 24% with TMP-SMX) 1

Babesiosis Treatment:

• Only 15% experienced adverse effects with atovaquone-azithromycin vs. 75% with clindamycin-quinine 6
• Only 1 patient required dose reduction or discontinuation 6

Serious Adverse Effects

Hepatotoxicity:

• Elevated liver enzymes, hepatitis, and fatal liver failure reported 1
• Monitor liver function tests

Hematologic:

• Methemoglobinemia, thrombocytopenia (postmarketing) 1

Dermatologic:

• Erythema multiforme, Stevens-Johnson syndrome, skin desquamation 1

Other Serious Reactions:

• Pancreatitis, acute renal impairment (postmarketing) 1
• Vortex keratopathy 1

Comparative Tolerability

Atovaquone demonstrates superior tolerability compared to standard agents:

• Fewer adverse events than TMP-SMX (63% vs. 72%) and pentamidine 1
• Significantly fewer discontinuations than clindamycin-quinine for babesiosis (1 patient vs. one-third of patients) 6
• Fewer gastrointestinal events than chloroquine-proguanil and fewer neuropsychiatric events than mefloquine for malaria 7

Drug Interactions

Contraindicated/Not Recommended:

• Rifampin or rifabutin: Significantly reduces atovaquone concentrations - concomitant use not recommended 1

Use with Caution:

• Tetracycline: Reduces atovaquone concentrations - monitor for loss of efficacy 1
• Metoclopramide: Reduces atovaquone concentrations - use only if other antiemetics unavailable 1
• Indinavir: Atovaquone reduces indinavir trough concentrations - monitor for loss of efficacy 1

Increased Atovaquone Concentrations:

• Fluconazole and prednisone increase atovaquone levels 5

Decreased Atovaquone Concentrations:

• Acyclovir, opiates, cephalosporins, rifampin, benzodiazepines 5

Clinical Pearls and Pitfalls

Common Pitfalls to Avoid

1. Food requirement: The most critical error is administering without food - this guarantees subtherapeutic levels and treatment failure
2. Severe disease: Do not use atovaquone for severe PCP or severe babesiosis - use IV pentamidine or clindamycin-quinine respectively
3. Rifamycin coadministration: Avoid concurrent rifampin/rifabutin - renders atovaquone ineffective
4. Malabsorption states: Recognize that diarrhea or GI disorders compromise absorption

Optimal Use Strategies

• For babesiosis: Atovaquone-azithromycin is preferred over clindamycin-quinine due to dramatically better tolerability (85% fewer adverse effects) 6
• Duration flexibility: Recent data supports low-dose atovaquone (750 mg/day) for PCP prophylaxis in lower-risk populations 4, 9
• Transition strategy: 84% of patients can successfully transition from atovaquone back to cotrimoxazole after initial contraindication resolves 3
• Monitoring: Regular review allows reassessment of initial indication and potential reinstatement of cotrimoxazole 3

Safety Profile

Lactation: Breastfeeding not recommended in HIV-1 infected mothers due to potential HIV transmission risk 1

Pregnancy: Limited data available; use only if benefit outweighs risk